leisure time -WSS

leisure time

author：entertainment 2025-10-01 14:40:06 - browse：41

Light micrograph of a fatty liver — Large vacuoles of triglyceride fat, accumulated inside liver cells. Adobe

SAN DIEGO — An experimental obesity drug from Eli Lilly significantly reduced liver fat in a small analysis, supporting further studies of the treatment against nonalcoholic fatty liver disease, an increasingly common condition that lacks approved treatments.

Among 98 patients with nonalcoholic fatty liver disease, those on the highest dose tested of the drug, retatrutide, experienced an 86% decrease in liver fat over 48 weeks, with most of the reduction occurring early on in treatment, according to data presented here at the American Diabetes Association conference Monday.

Additionally, 93% of people on the highest dose achieved resolution of fatty liver disease, defined as having 5% or less liver fat.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Why depression after traumatic brain injury is distinct

hotspot

knowledge

WSS

Life sciences investors close nearly $6 billion in new funds

Coloradans with cystic fibrosis could lose access to Trikafta

Ebola: Gilead Sciences antiviral shows promise as new treatment

Pushing for an NIH office for post

The health care issue Democrats can’t solve: hospital reform

UCLA team creates talking throat patch for voice disorders

leisure time

leisure time

Wikipedia

Affirmative action in medical school literally saved lives

John Green on his newest strategy for fighting tuberculosis

The high cost of giving birth even with insurance

Change Healthcare outage fallout shows need for new oversight

BioMarin wins approval for gene therapy to treat hemophilia A

UCLA team creates talking throat patch for voice disorders

Tori Bowie and the unacceptable rates of Black maternal death

Why scientists need input from humanists on sensitive research

Apple is now the first public company to be valued at $3 trillion

Readout Newsletter: CAR

focus

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Ebola: Gilead Sciences antiviral shows promise as new treatment

Explaining an after

Male and female sex labels in research insufficient, scientists say

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

President Biden's budget: Here's what you might have missed

focus

hotspot

knowledge

focus